62625-79-0Relevant academic research and scientific papers
SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists
Atobe, Masakazu,Naganuma, Kenji,Kawanishi, Masashi,Morimoto, Akifumi,Kasahara, Ken-Ichi,Ohashi, Shigeki,Suzuki, Hiroko,Hayashi, Takahiko,Miyoshi, Shiro
, p. 6569 - 6576 (2014/01/06)
We describe a medicinal chemistry approach for generating a series of 2-(1H-pyrazol-1-yl)thiazoles as EP1 receptor antagonists. To improve the physicochemical properties of compound 1, we investigated its structure-activity relationships (SAR).
Regioselective one-step synthesis of pyrazoles from alkynes and N-tosylhydrazones: [3+2] dipolar cycloaddition/[1,5] sigmatropic rearrangement cascade
Pérez-Aguilar, M. Carmen,Valdés, Carlos
supporting information, p. 7219 - 7223 (2013/07/26)
Rearrangement under control: A wide variety of 3,4,5- and 1,3,5-trisubstituted pyrazoles can be prepared from tosylhydrazones of ketones and terminal alkynes through the title reaction sequence (see scheme; Ts=4-toluenesulfonyl). The rearrangement, and th
NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS
-
Page/Page column 45, (2010/03/02)
Nitrogen-containing heterocyclic compounds represented by the following Formula (1) are provided. The compounds or salts thereof have a strong EP1 antagonistic activity when they are administered to a human or an animal, and they are useful as an effective component of a pharmaceutical agent for prophylaxis and/or treatment of an overactive bladder, for example. Furthermore, they are useful as an effective component of a pharmaceutical agent for the prophylaxis and/or treatment of symptoms including frequent urination, urinary urgency and urinary incontinence.
Structure-Activity Relationships Associated with 3,4,5-Triphenyl-1H-pyrazole-1-nonanoic Acid, a Nonprostanoid Prostacyclin Mimetic
Meanwell, Nicholas A.,Rosenfeld, Michael J.,Wright, J. J. Kim,Brassard, Catherine L.,Buchanan, John O.,et al.
, p. 389 - 397 (2007/10/02)
A series of phenylated pyrazoloalkanoic acid derivatives were synthesized and evaluated as inhibitors of ADP-induced human platelet aggregation. 3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (8d), with an IC50 of 0.4 μM, was the most potent inhibitor identi
